New drug aims to deepen remission in multiple myeloma
NCT ID NCT01242930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat intravenously, and some also continued lenalidomide maintenance. The study measured response improvement, progression-free survival, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imetelstat (GRN163L)
What this could lead to
If successful, imetelstat could help improve disease control in multiple myeloma patients who have not achieved a complete response after initial treatment.
What could go wrong
This is a small, early-phase trial with only 13 participants, so results may not apply broadly. The drug may not improve response rates or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center Johns Hopkins Hospital
Baltimore, Maryland, 21231, United States
-
University of Maryland Medical Center - M & S Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States